MDCX Research | Milton Maxwell

MDCX

Medicus Pharma Ltd.

1.8000

-0.0300-1.64%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

44.48M

P/E (TTM)

Basic EPS (TTM)

-2.23

Dividend Yield

Recent Filings

10-K

3/25/26Mar 25, 2026

8-K

SEPA share sales total $3.8M

3/6/26Mar 6, 2026

Medicus Pharma completed SEPA Advances under its February 2025 agreement with Yorkville, selling 4,471,038 common shares for $3,846,910 across 15 tranches from December 2025 to March 6, 2026. Part of proceeds prepaid a Yorkville debenture. Shares issued exempt under Section 4(a)(2). More sales possible.

8-K

ATM equity program launched

12/30/25Dec 30, 2025

Medicus Pharma entered an Equity Distribution Agreement on December 29, 2025, with Maxim Group and Yorkville Securities for an at-the-market offering of common shares up to $15,349,674. Agents earn a 3.0% commission on gross sales. Sales hinge on SEC effectiveness. No sales obligation exists.

8-K

Warrant exercise yields $5.1M

12/8/25Dec 8, 2025

Medicus Pharma inked a warrant inducement deal on December 5, 2025, prompting a holder to exercise 2,680,000 existing warrants at $1.92/share for ~$5.1M gross proceeds, closing ~December 8. In exchange, it issues new Series C/D warrants for 4,020,000 shares at $2.00/share, exercisable post-shareholder approval if needed, expiring June 5, 2031. Cash bolsters runway, yet adds dilution risk.

8-K

CFO resigns; Bonner appointed

12/1/25Dec 1, 2025

Medicus Pharma's CFO James Quinlan resigned effective November 28, 2025, after medical leave since September 12. President Carolyn Bonner, acting CFO in the interim, steps up permanently from December 1 under a five-year deal with $395,000 base salary and escalating bonuses to 100%. Leadership consolidates. Continuity holds amid clinical advances.

About

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.

CEO

Dr. Raza Bokhari M.B.A., M.D., MBA

IPO

11/14/2024

Website

https://medicuspharma.com

Sector

Healthcare

Industry

Drug Manufacturers - General